Holen Sie sich die Stockscreener-App
13.18
1.13%
-0.15
Vorhandelsmarkt:
13.30
0.12
+0.91%
Schlusskurs vom Vortag:
$13.33
Offen:
$13.22
24-Stunden-Volumen:
2.00M
Relative Volume:
1.31
Marktkapitalisierung:
$1.37B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-135.21M
KGV:
-9.2097
EPS:
-1.4311
Netto-Cashflow:
$-114.35M
1W Leistung:
+2.33%
1M Leistung:
-2.08%
6M Leistung:
+18.74%
1J Leistung:
+26.00%
1-Tages-Spanne:
$12.79
$13.51
1-Wochen-Bereich:
$12.47
$14.00
52-Wochen-Spanne:
$7.23
$14.93
Oric Pharmaceuticals Inc Stock (ORIC) Company Profile
Firmenname
Oric Pharmaceuticals Inc
Sektor
Branche
Telefon
(650) 388-5600
Adresse
240 E. GRAND AVE., SOUTH SAN FRANCISCO, CA
Compare ORIC vs VRTX, REGN, MRNA, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ORIC
Oric Pharmaceuticals Inc
|
13.18 | 1.37B | 0 | -135.21M | -114.35M | -1.4311 |
VRTX
Vertex Pharmaceuticals Inc
|
522.38 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
796.02 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
194.82 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
962.22 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
199.86 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Oric Pharmaceuticals Inc Stock (ORIC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-06-12 | Fortgesetzt | Stifel | Buy |
| 2026-05-15 | Hochstufung | Goldman | Neutral → Buy |
| 2026-01-07 | Eingeleitet | Piper Sandler | Overweight |
| 2025-11-20 | Eingeleitet | Evercore ISI | Outperform |
| 2025-11-18 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-09-04 | Fortgesetzt | Guggenheim | Buy |
| 2025-07-08 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2024-10-31 | Eingeleitet | Wells Fargo | Overweight |
| 2024-09-06 | Eingeleitet | Stifel | Buy |
| 2024-02-23 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-09-22 | Eingeleitet | Wedbush | Outperform |
| 2023-03-23 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2023-03-21 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-03-16 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2022-07-18 | Fortgesetzt | Oppenheimer | Perform |
| 2022-04-04 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-03-25 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2022-03-22 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-03-22 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-03-22 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-07-06 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-01-25 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-08-13 | Eingeleitet | Robert W. Baird | Outperform |
| 2020-08-06 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-08-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-05-19 | Eingeleitet | Citigroup | Neutral |
| 2020-05-19 | Eingeleitet | Guggenheim | Buy |
| 2020-05-19 | Eingeleitet | JP Morgan | Overweight |
| 2020-05-19 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Oric Pharmaceuticals Inc Aktie (ORIC) Neueste Nachrichten
ORIC Pharmaceuticals stock trades 10.7 percent below its 52-week high - AD HOC NEWS
Oric Pharmaceuticals (NASDAQ:ORIC) Shares Gap UpStill a Buy? - MarketBeat
Oric Pharmaceuticals (NASDAQ:ORIC) Coverage Initiated at BTIG Research - MarketBeat
BTIG initiates ORIC Pharmaceuticals stock coverage with buy rating - Investing.com
BTIG initiates ORIC Pharmaceuticals stock coverage with buy rating By Investing.com - Investing.com Canada
BTIG initiates coverage of ORIC Pharmaceuticals with Buy rating, $26 price target - TradingView
(ORIC) Volatility Zones as Tactical Triggers - Stock Traders Daily
ORIC Falls After Hours On Safety Concerns Around Prostate Cancer Candidate At Higher Doses - Stocktwits
Oric Pharmaceuticals Inc (NYSE: ORIC) Share Price, ORIC Stock News, ORIC Share Price & Updates - kalkine.com.au
We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth - Moomoo
Oric Pharmaceuticals (ORIC) Stock Analysis: A 60% Upside Potential with Strong Buy Ratings in Biotech - DirectorsTalk Interviews
Why ORIC Pharmaceuticals (ORIC) Is Back In The Spotlight - simplywall.st
ORIC Pharmaceuticals Inc. (US68622P1093.SG) stock price, news, quote and history - Yahoo Finance UK
ORIC (ORIC) Doubles Down On Prostate Cancer With Phase 3 Launch - AlphaStreet
ORIC: Advancing late-stage cancer programs with strong safety differentiation and robust financial runway - TradingView
Squarepoint Ops LLC Purchases Shares of 344,343 Oric Pharmaceuticals, Inc. $ORIC - MarketBeat
Precision Trading with Oric Pharmaceuticals Inc. (ORIC) Risk Zones - Stock Traders Daily
ORIC: Advancing late-stage prostate and lung cancer programs with robust funding and global trials - TradingView
ORIC: Phase III trials and robust funding position support late-stage oncology pipeline growth - TradingView
ORIC Pharmaceuticals at Wells Fargo conference: late-stage pipeline in focus - Investing.com Canada
Oric Pharmaceuticals joins 2026 Cantor Global Healthcare Conference fireside chat: Can ORIC break above $12.51? - Traders Union
ORIC: Advancing late-stage cancer therapies with strong efficacy, safety, and major market potential - TradingView
Enterprise value to revenue forward of Oric Pharmaceuticals, Inc. – NASDAQ:ORIC - TradingView
Enterprise value to revenue forward of Oric Pharmaceuticals, Inc. – MUN:4TZ - TradingView
ORIC stock holds steady as biotech eyes next trial and earnings - AD HOC NEWS
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Himalayas-1: Bayer and ORIC Double Down on Prostate Cancer With New Phase 3 Combo Trial - TipRanks
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewswire
ORIC stock holds firm as biotech valuation nears 0.93 billion USD - ad-hoc-news.de
(ORIC) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Oric Pharmaceuticals stock holds above $13 as BlackRock boosts stake - ad-hoc-news.de
Oric Pharmaceuticals (NASDAQ: ORIC) CFO sells 77,000 shares - Stock Titan
ORIC Pharmaceuticals (NASDAQ: ORIC) officer plans $3.1M stock sale - Stock Titan
Blue Owl Capital Holdings LP Invests $4.33 Million in Oric Pharmaceuticals, Inc. $ORIC - MarketBeat
Oric Pharmaceuticals (NASDAQ:ORIC) Sets New 12-Month HighHere's Why - MarketBeat
Oric (ORIC) Earnings Report: EPS Misses Its Estimate in Latest Trading; After Earnings: The Stock Gains 4.04% in the Latest SessionForward EPS Estimate - vinanet.vn
BCAX Stock Price and Chart — NASDAQ:BCAX - TradingView
HC Wainwright Issues Pessimistic Outlook for ORIC Earnings - MarketBeat
Understanding Momentum Shifts in (ORIC) - Stock Traders Daily
ORIC Pharmaceuticals (ORIC) Slips 1.17% as Biotech Stock Approaches Key Support at $12.89Price Target - dars.gov.et
Price to book forward of Oric Pharmaceuticals, Inc. – HAM:4TZ - TradingView
What is HC Wainwright's Forecast for ORIC Q1 Earnings? - MarketBeat
ORIC Pharmaceuticals, Inc. (ORIC) options chain - Yahoo Finance Australia
ORIC PHARMACEUTICALS, INC. : H.C. WAINWRIGHT RAISES TARGET PRICE TO $27 FROM $25 - webull.com
ORIC Maintained by HC Wainwright & Co. -- Price Target Raised to $27 - GuruFocus
H.C. Wainwright raises ORIC Pharmaceuticals price target to $27 on pipeline progress - Investing.com
H.C. Wainwright Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Raises Target Price to $27 - Moomoo
Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
ORIC Pharmaceuticals (ORIC) Q2 Losses Put Valuation In Focus As Shares Rally - Sahm
Dimensional Fund Advisors LP Boosts Holdings in Oric Pharmaceuticals, Inc. $ORIC - MarketBeat
Is ORIC Pharmaceuticals' (ORIC) Equity-Funded ESOP Masking or Clarifying Its Widening Net Losses? - Yahoo Finance
Finanzdaten der Oric Pharmaceuticals Inc-Aktie (ORIC)
Umsatz
Nettogewinn
Free Cashflow
ENV
Oric Pharmaceuticals Inc-Aktie (ORIC) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Piscitelli Dominic | Chief Financial Officer |
Aug 26 '26 |
Sale |
13.69 |
77,000 |
1,053,814 |
69,828 |
1.11%
1.87%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):